Biomea Fusion

BIOMEA FUSION INC

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Biomea Fusion Inc

Earnings

Press Releases

Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

News

Biomea Fusion's BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

Health Care

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

IPOs

Biomea Fusion Announces Proposed Public Offering of Securities

Financing

Biomea Fusion Announces Pricing of Public Offering of Securities

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

General

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Management

Biomea Fusion Appoints Julianne Averill to its Board of Directors

Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights

AVAI

BLCO

BMEA

EYEN

OTLK

Alpha Cognition

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anixa Biosciences

Atossa Therapeutics

Avalo Therapeutics

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Coya Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Elutia

Fate Therapeutics

HilleVax

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

IO Biotech

MDxHealth

Macrogenics

Oncolytics Biotech

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Skye Bioscience

Spero Therapeutics

Surrozen

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

TScan Therapeutics

XBiotech

Citigroup

Scotiabank

D. Boral Capital

Piper Sandler

HC Wainwright & Co.

Comments

Biomea Fusion

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL